1. Scrip
  2. >>Archive

Protein Therapeutics Inc.

 
• By Stephen Levin

A major problem in treating rheumatoid arthritis is that current drugs cause numerous, often serious, side effects. Protein Therapeutics Inc. has developed an oral formulation of human gammaglobulin (higG) that may effectively treat rheumatoid arthritis without side effects.

A major problem in treating rheumatoid arthritis is that current drugs cause numerous, often serious, side effects. Protein Therapeutics Inc. has developed an oral formulation of human gammaglobulin (hIgG) that, the company claims, may effectively treat rheumatoid arthritis without side effects. In addition, hIgG appears to act at the initiation site of the disease, as opposed to simply suppressing disease-related symptoms as several currently prescribed drugs do, says the company's founder and president, Leon E. Barstow, PhD.

Research suggests rheumatoid arthritis may be an autoimmune response activated by superantigens that overstimulate the immune system. Gammaglobulin contains antibodies...

More from Archive

Final Chance To Have Your Say: Take Scrip's Reader Survey This Week

 
• By Eleanor Malone

Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.

Shape Our Content: Take The Reader Survey

 
• By Eleanor Malone

Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in the coverage topics, content format or the method in which you receive and access Scrip, or if you love it how it is, now is the time to have your voice heard.

Galapagos Expands Point-Of-Care CAR-T Study To The US

 
• By Andrew McConaghie

CEO Paul Stoffels said gaining US clearance for an IND for its novel CAR-T product was demanding, but now opens up a pathway towards a pivotal study starting in 2025.

Analysts Split On Eisai’s Chances Of Changing EU Regulator’s Mind On Leqembi

 
• By Andrew McConaghie

A final rejection of Leqembi could also spell the same fate for Lilly’s rival drug but public outcry and demand for Alzheimer’s therapies might force the regulator’s hand

More from Scrip

Taiho’s Oral, Mutation-Agnostic DMD Candidate Misses Phase III Endpoint

 
• By Lisa Takagi

The oral, twice-daily candidate was expected to control decline in motor function in DMD patients regardless of their gene mutations.

Finance Watch: Two New Venture Capital Funds Provide $600m For Biopharma

 
• By Mandy Jackson

Private Company Edition: Catalio raised more than $400m for its fourth health care-focused VC fund, while AN Venture Partners raised $200m for Japan and beyond. In VC financings, among a dearth of mega rounds, Neuron23’s $96.5m series D is the largest round in recent weeks.

ProKidney Pins Hopes On Accelerated Approval For Rilparencel

 
• By Alaric DeArment

After posting encouraging Phase II results, the company plans to meet with the US FDA about using data from an ongoing Phase III study for an accelerated approval.